Safety and tolerability of the new antidepressants

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 6, 1997, Pages 26-31

  Craig Nelson, J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLONAZEPAM; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; NEW DRUG; NORTRIPTYLINE; PAROXETINE; PETHIDINE; PLACEBO; SERTRALINE; VENLAFAXINE;

AGITATION; ARTICLE; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HEART PALPITATION; HUMAN; NERVOUSNESS; PRIORITY JOURNAL; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER; HEADACHE; HUMANS; MIANSERIN; NAUSEA; SEROTONIN UPTAKE INHIBITORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TRIAZOLES;

EID: 1842375625     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150(suppl 4): 1-26
2. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53
3. Reimherr FW, Chouinard G, Conn CK, et al. Antidepressant efficacy of sertraline: a double-blind, placebo-and amitriptyline-controlled multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51(12, suppl B):18-27
4. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-241
5. Montgomery SA, Bebbington P, Cowen P, et al. Guidelines for treating depressive illness with antidepressants: a statement from the British Association for Psychopharmacology. J Psychopharmacol 1992;7:19-23
6. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16:715-730
7. Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. JAMA. In press
8. Laghrissi-Thode F, Kennedy J, Nelson JC, et al. Nortriptyline versus paroxetine in depressed ischemic heart disease patients: a multicenter randomized double-blind clinical trial. Presented at the annual meeting of the American College of Neuropharmacology; December 1995; San Juan, Puerto Rico
9. Cassidy WL, Flanagan NB, Spellman M, et al. Clinical observations in manic depressive disease. JAMA 1957;164:1535-1546
10. Nelson JC, Jatlow P, Quinlan DM. Subjective side effects during desipramine treatment. Arch Gen Psychiatry 1984;41:55-59
11. Serzone (nefazodone). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1996:771-775
12. Nelson JC, Mazure CM, Jatlow PI. Characteristics of desipramine-refractory depression. J Clin Psychiatry 1994;55:12-19
13. Asberg M, Cronholm B, Sjoquist F, et al. Correlation of subjective side effects with plasma concentrations of nortriptyline. BMJ 1970;4:18-21
14. Glassman AH, Bigger JT, Giardina EGV, et al. Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet 1979;1:468-472
15. Roose SP, Glassman AH, Giardina EGV, et al. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987;44:273-275
16. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993;54:289-299
17. Dubovsky SL, Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 1995;56(suppl 2):38-48
18. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996;57(suppl 2):31-38
19. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56(suppl 6):12-21
20. Wernicke JF, Dunlop SR, Dornseif BE, et al. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987;23;1:164-168
21. Wernicke JF, Dunlop SR, Domseif BE, et al. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988;24;1:183-188
22. Remeron (mirtazapine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1996:1878-1881
23. Tulen JH, Bruijn JA, de Man KJ, et al. Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (Org 3770). J Clin Psychopharmacol 1996;16:135-145
24. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993;54:459-465
25. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10(suppl4):37-45
26. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713
27. Balon R, Berchou R. Hematologic side effects of psychotropic drugs. Psychosomatics 1986;27:119-127
28. Heimpel H. Drug-induced agranulocytosis. Medical Toxicology and Adverse Drug Experience 1988;3:449-462
29. Tohen M, Castillo J, Baldessarini RJ, et al. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 1995;152:413-418
30. Frazer A. Antidepressants. J Clin Psychiatry 1997;58(suppl 6):9-25